Takeda (TYO:4502) said today it is collaborating with Cambridge Cognition Holdings and Ctrl Group Ltd joint Cognition Kit to pilot study of a specially designed Apple (NSDQ:AAPL) Watch application to assess cognitive function in patients with major depressive disorder.
The Cognition Kit is designed to assess cognitive symptoms in patients with MDD and move patient care and monitoring into their daily lives, according to the groups involved.
The collaboration is the 1st for Cognition Kit Limited since launching its wearable cognitive technology last year, the company said.
“By combining wearable technology with world leading neuroscience, we’ve created an app that collects real time passive and active high-frequency mental health data. Being able to access data regularly from daily life can help clinical decision making. Healthcare professionals can obtain patient data and increase patient engagement in their treatment,” Cognition Kit’s Jenny Barnett said in a prepared statement.
The study is slated to pick up 30 participants with a clincial diagnosis of mild to moderate depression who’ve been prescribed antidepressants for MDD, and will examine feasibility and compliance with the system to explore how measures of mood and cognition on wearable tech compare to more traditional testing.
“Takeda is committed to CNS and the mental health community. This collaboration is part of our strategy to embrace new technology to better understand the patient experience and assist healthcare professionals in creating improved patient care pathways,” Takeda external partnerships VP Nicole Mowad-Nassar said in a press release.
The groups are hopeful that the study will begin in the 1st half of 2017.